MORPHOSYS AG/ DE0006632003 /
8/1/2024 4:58:21 PM | Chg. -0.05 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
67.90EUR | -0.07% | 5 Turnover: 339.50 |
-Bid Size: - | -Ask Size: - | 2.54 bill.EUR | - | - |
GlobeNewswire
7/16
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of M...
GlobeNewswire
6/3/2021
CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire
6/2/2021
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire
4/27/2020
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire
4/23/2019
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire
4/23/2019
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire
1/31/2019
Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
GlobeNewswire
9/13/2018
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire
9/13/2018
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire
9/12/2018
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire
9/12/2018
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire
7/19/2018
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire
7/19/2018
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atop...
GlobeNewswire
7/19/2018
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire
5/1/2018
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire
5/1/2018
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire
2/17/2018
Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...